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To the editor
Non-adherence and suboptimal inhaler technique are 
major problems in patients with obstructive lung disease. 
Less than one third of patients use their inhaler correctly, 
and the inhaler technique has not improved over the past 
40  years despite innovations in devices [1]. Suboptimal 
inhaler use leads to more side effects, poor symptom 
control, reductions in health-related quality of life, exac-
erbations and consequently, increased healthcare costs 
[2, 3]. In order to achieve and maintain a correct inhaler 
technique, innovative approaches for education includ-
ing mobile health applications (mHealth apps) are being 
explored [4]. The My Puff app, in which patients can 
choose their inhaler to watch instruction videos, could 
be an innovative approach to continue inhaler tech-
nique training between care visits. However, to date, the 
feasibility to integrate this app in patient care as well as 
the effectiveness of this app has not yet been evaluated. 
Therefore, we aimed to measure inhaler technique and 
disease control improvement three months after a phar-
maceutical care intervention, comparing aid to install 
and use the My Puff app to providing standard informa-
tion leaflets for continued home education.
This open randomized controlled trial was carried out 
between March and December 2018 in nine Belgian com-
munity pharmacies. Dutch-speaking adult patients with 
self-reported chronic asthma or Chronic Obstructive 
Pulmonary Disease (COPD) on registered inhaler ther-
apy were included. Seventy patients were randomized to 
the app group (n = 37; 53%) or leaflet group (n = 33; 47%) 
with a randomized (computer-generated) block design 
per participating pharmacy. All patients were asked to 
demonstrate their inhaler technique, and received feed-
back as well as a demonstration of the correct technique 
with a similar placebo device. In order to continue inhaler 
training at home, patients in the control group received 
a standard leaflet with inhaler instructions developed 
by the Lung Foundation on behalf of the Lung Alliance 
Netherlands. Patients in the intervention group received 
maximum assistance to download and use the My Puff 
app (version 1.0.3–1.0.4), including a leaflet contain-
ing the Quick Response code of the app and guidance to 
install and use. My Puff is a free app with video-assisted 
inhaler instructions (≈ 3 min), developed by the Belgian 
Respiratory Society (BeRS) in 2017 (https ://www.belgi 
anres pirat oryso ciety .be/nl/mypuff ). Patients’ inhaler 
technique was rated by the investigator using a check-
list per device, and disease control was assessed by the 
Asthma Control Test® (ACT) and the COPD assess-
ment Test® (CAT). A score increase of ≥ 3 for ACT and 
decrease by ≥ 2 for CAT was regarded as the minimum 
clinically important difference (MCID), and the potential 
impact of the intervention on this primary outcome was 
analyzed using a logistic regression model [5, 6]. Base-
line characteristics of the 70 enrolled patients, using 133 
inhalers in total, are presented in Table 1. According to 
the Global Initiative for Chronic Obstructive Lung Dis-
ease (GOLD) classification, 18% COPD/asthma-COPD 
overlap patients were classified GOLD A (n = 7), 49% 
patients GOLD B (n = 19), 3% patient GOLD C (n = 1) 
and 31% patients GOLD D (n = 12) based on the exacer-
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Table 1 Baseline demographic and clinical characteristics of the study patients
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ACO, asthma-COPD overlap; DPI, dry powder inhaler; MDI, metered-dose inhalers; SMI, soft 
mist inhalers; SABA, short-acting β2-agonist, SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting 
muscarinic antagonist; ACT, Asthma Control Test; CAT, COPD Assessment Test
Total (n = 70) Application (n = 37) Leaflet (n = 33)
Age in years, median (Q1–Q3) 64 (55–73) 66 (56–73) 63 (47–72)
Female, n (%) 39 (56) 20 (54) 19 (58)
BMI in kg/m², mean (SD) 26 (5) 26 (4) 27 (5)
Asthma, n (%) 31 (44) 18 (49) 13 (39)
COPD, n (%) 27 (39) 16 (43) 11 (33)
ACO, n (%) 12 (17) 3 (8) 9 (27)
Time since diagnosis in years, median (Q1–Q3) 13 (5–28) 15 (7–29) 10 (4–31)
Never smoker, n (%) 24 (34) 12 (32) 12 (36)
Past smoker, n (%) 32 (46) 18 (49) 14 (42)
Current smoker, n (%) 14 (20) 7 (19) 7 (21)
Pack-years among ever smokers, median (Q1-Q3) 30 (11–42) 31 (20–48) 26 (8–36)
Primary education, n (%) 11 (16) 4 (11) 7 (21)
Lower secondary education, n (%) 17 (24) 11 (30) 6 (18)
Upper secondary education, n (%) 22 (31) 14 (38) 8 (24)
Higher education (Non-university), n (%) 14 (20) 5 (14) 9 (27)
Higher education (University), n (%) 6 (9) 3 (8) 3 (9)
Allergy, n (%) 41 (59) 22 (59) 19 (58)
Chronic bronchitis, n (%) 37 (53) 21 (57) 16 (48)
Influenza vaccination, n (%) 44 (63) 22 (59) 22 (67)
≥ 1 exacerbation in preceding year, n (%) 34 (49) 12 (32) 22 (67)
≥ 1 severe exacerbation in preceding year, n (%) 8 (11) 4 (11) 4 (12)
≥ 1 course of antibiotics in preceding year, n (%) 46 (66) 21 (57) 25 (76)
≥ 1 course of oral corticosteroids in preceding year, n (%) 28 (40) 12 (32) 16 (48)
Handgrip strength dominant hand in kg, mean (SD) 30 (11) 31 (12) 29 (9)
1 inhaler, n (%) 24 (34) 15 (41) 9 (27)
2 inhalers, n (%) 31 (44) 13 (35) 18 (55)
3 inhalers, n (%) 13 (19) 9 (24) 4 (12)
4 inhalers, n (%) 2 (3) 0 (0) 2 (6)
DPI(s), n (%) 30 (43) 19 (51) 11 (33)
MDI(s), n (%) 8 (11) 3 (8) 5 (15)
SMI(s) (combinations), n (%) 11 (16) 3 (8) 8 (24)
DPI + MDI, n (%) 21 (30) 12 (32) 9 (27)
Single device, n (%) 38 (54) 22 (59) 16 (48)
SABA, n (%) 11 (16) 5 (14) 6 (18)
SABA/SAMA, n (%) 22 (31) 12 (32) 10 (30)
ICS, n (%) 2 (3) 1 (3) 1 (3)
LABA, n (%) 2 (3) 1 (3) 1 (3)
ICS/LABA, n (%) 36 (51) 19 (51) 17 (52)
LABA/LAMA, n (%) 7 (10) 5 (14) 2 (6)
ICS/LABA/LAMA, n (%) 23 (33) 11 (30) 12 (36)
Oral (leukotriene receptor antagonist or theophylline), n (%) 13 (19) 8 (22) 5 (15)
ACT score among asthma/ACO patients, median (Q1-Q3) 19 (13–23) 20 (14–24) 18 (13–22)
CAT score among COPD/ACO patients, median (Q1–Q3) 16 (10–22) 14 (10–21) 18 (11–24)
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The inhaler technique scored generally poor at base-
line with half of patients making critical errors (n = 36, 
51%). The mean inhaler technique score was signifi-
cantly improved in both groups 3 months after the 
pharmacist intervention (Fig.  1), with no between-
group differences in favor of the app over the leaflet 
for the continued home education (p = 0.116). In con-
trast, the proportion of patients achieving the MCID of 
improved disease control was 54% in the leaflet group 
and 28% in the app group resulting in a three times 
higher odds to achieve the MCID in the leaflet group 
compared to the app group (OR 2.95; 95% CI 1.01–
8.60; p = 0.048). The mean age of the patients might 
have favored the leaflet. The positive effect on disease 
control seemed primarily driven by asthma control 
with an average 2 point improvement (p = 0.05). This 
is in line with inhaler technique interventions at com-
munity pharmacies demonstrating benefit for asthma 
control, although a consistent and important clinical 
benefit could not be observed in all studies [7]. Our 
study could not detect significant changes in disease 
control for COPD patients, which is in accordance 
with the pharmaceutical care intervention for COPD 
patients (PHARMACOP) study [8]. The pharmacist 
was not able to install the app on any of patients’ smart-
phones during the pharmacy visit due to the lack of a 
smartphone or code to the app store or mobile data. 
Since this pragmatic trial aimed to test the effectiveness 
of the app in daily practice, having a smartphone was 
no eligibility criterion [9]. Only a quarter of patients 
(n = 8) installed the app at home and only 13% of 
patients (n = 4) actively used it. In contrast, more than 
half of patients (n = 16, 57%) actively used the leaflet. 
Importantly, the users of continued home education 
made already less critical errors at baseline (n = 7/20, 
35%). In contrast, non-users are likely to benefit most 
since they had a higher baseline error rate (n = 25/40, 
63%). The most reported barrier for both the app and 
leaflet was not finding it necessary, but the app had an 
additional barrier of never using apps or a smartphone, 
although three third of the app users fully agreed that 
the app ensures how to use medication, and found that 
the app had a positive effect on disease control. Face-
to-face training could be important to improve inhaler 
technique given mixed success of multi-media trainings 
at distance [7]. Despite the crucial aspect of inhaler 
training in asthma and COPD management, still 6% 
reported to not being instructed on their inhaler tech-
nique by any caregiver before. This disappointing result 
is almost unchanged in comparison with the PHAR-
MACOP study in 2011 (7%), leaving room for further 
improvement [8]. Interestingly, females were more 
poorly controlled at baseline and seemed to have used 
any of the two approaches more, but the differences 
were not significant. 
The small sample size might be a limitation of the 
study though continuation was not considered mean-
ingful because of the limited use of the app in real life, 
even after maximally guided instructions. Still, a pre-
post analysis showed a significant improved inhaler 
technique most likely driven by the hands-on training 
by the pharmacist. No spirometry results were available 
to confirm the diagnosis or to classify severity. How-
ever, this limitation supports the pragmatic framework. 
The major shortcomings in the use of the app highlight 
the need for further research to include features asso-
ciated with improved adoption and adherence. eHealth 
literacy, motivation, and preferences of patients should 
be considered to achieve improvement of inhaler tech-
nique by personalized trainings at the community level. 
Our study results inquire at least as much interest in 
further improvement of inhaler technique trainings by 
health care providers as there is for app development 
to further decrease disease burden of patients with 
obstructive lung disease in real life practice.
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